The Science of Aerosol Delivery in Cystic FibrosisGELLER, David E.Pediatric pulmonology. 2008, Vol 43, Num 9, issn 8755-6863, S5-S17, SUPAArticle

Aerosol Antibiotics in Cystic FibrosisGELLER, David E.Respiratory care. 2009, Vol 54, Num 5, pp 658-670, issn 0020-1324, 13 p.Conference Paper

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ TechnologyGELLER, David E; WEERS, Jeffry; HEUERDING, Silvia et al.Journal of aerosol medicine and pulmonary drug delivery. 2011, Vol 24, Num 4, pp 175-182, issn 1941-2711, 8 p.Article

43rd Respiratory Care Journal Conference on Respiratory Care and Cystic Fibrosis, Part IRUBIN, Bruce K; GELLER, David E.Respiratory care. 2009, Vol 54, Num 5, issn 0020-1324, 99 p.Conference Proceedings

New Aerosol Delivery Devices for Cystic FibrosisKESSER, Kenneth C; GELLER, David E.Respiratory care. 2009, Vol 54, Num 6, pp 754-768, issn 0020-1324, 15 p.Conference Paper

Clinical side effects during aerosol therapy : Cutaneous and ocular effects. DiscussionGELLER, David E; JANSSENS, Hettie.Journal of aerosol medicine. 2007, Vol 20, issn 0894-2684, S100-S109, SUP1Conference Paper

A Technical Feasibility Study of Dornase Alfa Delivery with eFlow^® Vibrating Membrane Nebulizers: Aerosol Characteristics and Physicochemical StabilitySCHERER, Thomas; GELLER, David E; OWYANG, Laura et al.Journal of pharmaceutical sciences. 2011, Vol 100, Num 1, pp 98-109, issn 0022-3549, 12 p.Article

Cystic Fibrosis and the Respiratory Therapist: A 50-Year PerspectiveVOLSKO, Teresa A.Respiratory care. 2009, Vol 54, Num 5, pp 587-594, issn 0020-1324, 8 p.Conference Paper

Monitoring Respiratory Disease Severity in Cystic FibrosisDAVIES, Jane C; ALTON, Eric Wfw.Respiratory care. 2009, Vol 54, Num 5, pp 606-617, issn 0020-1324, 12 p.Conference Paper

Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. DiscussionGELLER, David E; SMALDONE; ATKINS et al.Respiratory care. 2005, Vol 50, Num 10, pp 1313-1322, issn 0020-1324, 10 p.Conference Paper

New liquid aerosol generation devices: Systems that force pressurized liquids through nozzles. DiscussionGELLER, David E; GOMEZ; DENNIS et al.Respiratory care. 2002, Vol 47, Num 12, pp 1392-1405, issn 0020-1324, 14 p.Conference Paper

The I-neb Adaptive Aerosol Delivery System Enhances Delivery of α1-Antitrypsin with Controlled InhalationGELLER, David E; KESSER, Kenneth C.Journal of aerosol medicine and pulmonary drug delivery. 2010, Vol 23, issn 1941-2711, S55-S59, SUP1Article

A Multi-Center Controlled Trial of Growth Hormone Treatment in Children With Cystic FibrosisSTALVEY, Michael S; ANBAR, Ran D; KONSTAN, Michael W et al.Pediatric pulmonology. 2012, Vol 47, Num 3, pp 252-263, issn 8755-6863, 12 p.Article

Cystic Fibrosis: Pathogenesis and Future Treatment StrategiesRATJEN, Felix A.Respiratory care. 2009, Vol 54, Num 5, pp 595-605, issn 0020-1324, 11 p.Conference Paper

Pulmonary exacerbations in cystic fibrosisRABIN, Harvey R; BUTLER, Steven M; WOHL, Mary Ellen B et al.Pediatric pulmonology. 2004, Vol 37, Num 5, pp 400-406, issn 8755-6863, 7 p.Article

Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway InfectionTRAPNELL, Bruce C; MCCOLLEY, Susanna A; KISSNER, Dana G et al.American journal of respiratory and critical care medicine. 2012, Vol 185, Num 2, pp 171-178, issn 1073-449X, 8 p.Article

Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationFLUME, Patrick A; LIOU, Theodore G; BOROWITZ, Drucy S et al.Chest (American College of Chest Physicians). 2012, Vol 142, Num 3, pp 718-724, issn 0012-3692, 7 p.Article

The CHOICE survey: high rates of persistent and uncontrolled asthma in the United StatesCOLICE, Gene L; OSTROM, Nancy K; GELLER, David E et al.Annals of allergy, asthma, & immunology. 2012, Vol 108, Num 3, pp 157-162, issn 1081-1206, 6 p.Article

Infection Control in Cystic Fibrosis: Cohorting, Cross-Contamination, and the Respiratory TherapistO'MALLEY, Catherine A.Respiratory care. 2009, Vol 54, Num 5, pp 641-657, issn 0020-1324, 17 p.Conference Paper

Novel tobramycin inhalation powder in cystic fibrosis subjects : Pharmacokinetics and safetyGELLER, David E; KONSTAN, Michael W; SMITH, Jeffrey et al.Pediatric pulmonology. 2007, Vol 42, Num 4, pp 307-313, issn 8755-6863, 7 p.Article

Long-Term Inhaled Dry Powder Mannitol in Cystic Fibrosis: An International Randomized StudyAITKEN, Moira L; BELLON, Gabriel; ZUCKERMAN, Jonathan B et al.American journal of respiratory and critical care medicine. 2012, Vol 185, Num 6, pp 645-652, issn 1073-449X, 8 p.Article

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis SubjectsGELLER, David E; FLUME, Patrick A; GRIFFITH, David C et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 6, pp 2636-2640, issn 0066-4804, 5 p.Article

Tobramycin Inhalation Powder for P. aeruginosa Infection in Cystic Fibrosis: The EVOLVE TrialKONSTAN, Michael W; GELLER, David E; MINIC, Predrag et al.Pediatric pulmonology. 2011, Vol 46, Num 3, pp 230-238, issn 8755-6863, 9 p.Article

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosaGELLER, David E; FLUME, Patrick A; STAAB, Doris et al.American journal of respiratory and critical care medicine. 2011, Vol 183, Num 11, pp 1510-1516, issn 1073-449X, 7 p.Article

Risk Factors Associated with Depressive Symptoms in Caregivers of Children with Type 1 Diabetes or Cystic FibrosisDRISCOLL, Kimberly A; BENNETT JOHNSON, Suzanne; BARKER, David et al.Journal of pediatric psychology. 2010, Vol 35, Num 8, pp 814-822, issn 0146-8693, 9 p.Article